{"disease":{"id":"juvenile-psoriatic-arthritis","name":"Juvenile psoriatic arthritis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"tofacitinib","indication_name":"Juvenile psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeljanz","generic_name":"tofacitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes","drug_class":"JAK inhibitor","quality_score":97,"revenue":"1800","mechanism":"Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs."},{"drug_id":"tasocitinib","indication_name":"Juvenile psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasocitinib","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"xeljanz-xr","indication_name":"Juvenile psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeljanz","generic_name":"Tofacitinib Citrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes","drug_class":"JAK inhibitor","quality_score":72,"revenue":null,"mechanism":"Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation."},{"drug_id":"tofa","indication_name":"Juvenile psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOFA","company_name":"","drug_phase":"marketed","molecular_target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","drug_class":"","quality_score":35,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT07000916","title":"Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT07087912","title":"Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":477,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT04018599","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Fresenius Kabi SwissBioSim GmbH","has_results":false},{"nct_id":"NCT05715463","title":"Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":101,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03031782","title":"Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04804553","title":"Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06869551","title":"A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03769168","title":"An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05767047","title":"A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06668181","title":"An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT05252533","title":"A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05545839","title":"Transition to Adulthood Through Coaching and Empowerment in Rheumatology","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT06751238","title":"Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":15},"guidelines":[{"drug_id":"etanercept","guideline_body":"FDA label","recommendation":"Enbrel is indicated for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients 2 years of age and older.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}